Targeted delivery of probiotics to enhance gastrointestinal stability and intestinal colonisation

被引:107
作者
Dodoo, Cornelius C. [1 ]
Wang, Jie [1 ]
Basit, Abdul W. [1 ,2 ]
Stapleton, Paul [1 ]
Gaisford, Simon [1 ]
机构
[1] UCL, UCL Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England
[2] Intract Pharma, 29-39 Brunswick Sq, London WC1N 1AX, England
关键词
Probiotics; Gastric acid tolerance tests; Phloral (R) coating technology; Intestinal colonisation; IN-VITRO ADHERENCE; SACCHAROMYCES-BOULARDII; LACTOBACILLUS STRAINS; ULCERATIVE-COLITIS; LACTOCOCCUS-LACTIS; PROTECTIVE AGENTS; REHYDRATION MEDIA; HPMC CAPSULES; SURVIVAL; BACTERIA;
D O I
10.1016/j.ijpharm.2017.07.068
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this work was to assess the viability of some commercial probiotics after exposure to gastric acid and the possibility of modifying these formulations for delivery into the distal parts of the intestines. Gastrointestinal tolerance testing was conducted for three commercial probiotics and an in-house freeze-dried Lactobacillus acidophilus strain. The contents of the commercial products and the in-house freeze-dried strain were then loaded into capsules for site-specific delivery into the colon using the Phloral (R) coating technology; the viability upon release was then ascertained. An assessment of the potential of these products to adhere to intestinal cells was also conducted. The results showed that all the commercial products contained the minimum number of probiotic strains as indicated on their respective packages. When gastric acid tolerance tests were performed on these products, all the commercial probiotics and the prepared freeze-dried strain demonstrated over 10(6) CFU reductions within 5 min. When these were encapsulated for site-specific delivery into the distal parts of the gut, viabilities of approximately 90% were obtained after these capsules had been initially deposited in gastric acid for 2 h. An evaluation of the ability of the probiotic formulations to adhere to intestinal cells demonstrated adhesion in the range 64-76% for the products evaluated. The need to target the delivery of probiotics into the intestines has been demonstrated here as this offers a greater potential for colonisation of the intestines once the harshness of the stomach has been overcome. (c) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 52 条
[1]   Drying techniques of probiotic bacteria as an important step towards the development of novel pharmabiotics [J].
Broeckx, Geraldine ;
Vandenheuvel, Dieter ;
Claes, Ingmar J. J. ;
Lebeer, Sarah ;
Kiekens, Filip .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 505 (1-2) :303-318
[2]   In vitro gastric survival of commercially available probiotic strains and oral dosage forms [J].
Caillard, Romain ;
Lapointe, Nicolas .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 519 (1-2) :125-127
[3]  
Charteris WP, 1998, J APPL MICROBIOL, V84, P759
[4]   Enteric coated HPMC capsules designed to achieve intestinal targeting [J].
Cole, ET ;
Scott, RA ;
Connor, AL ;
Wilding, IR ;
Petereit, HU ;
Schminke, C ;
Beckert, T ;
Cadé, D .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 231 (01) :83-95
[5]   Effect of protective agents, rehydration media and initial cell concentration on viability of Pantoea agglomerans strain CPA-2 subjected to freeze-drying [J].
Costa, E ;
Usall, J ;
Teixidó, N ;
Garcia, N ;
Viñas, I .
JOURNAL OF APPLIED MICROBIOLOGY, 2000, 89 (05) :793-800
[6]   Isolation and characterization of human colonic bacteria able to hydrolyse chlorogenic acid [J].
Couteau, D ;
McCartney, AL ;
Gibson, GR ;
Williamson, G ;
Faulds, CB .
JOURNAL OF APPLIED MICROBIOLOGY, 2001, 90 (06) :873-881
[7]   Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis [J].
D'Haens, G. R. ;
Sandborn, W. J. ;
Zou, G. ;
Stitt, L. W. ;
Rutgeerts, P. J. ;
Gilgen, D. ;
Jairath, V. ;
Hindryckx, P. ;
Shackelton, L. M. ;
Vandervoort, M. K. ;
Parker, C. E. ;
Muller, C. ;
Pai, R. K. ;
Levchenko, O. ;
Marakhouski, Y. ;
Horynski, M. ;
Mikhailova, E. ;
Kharchenko, N. ;
Pimanov, S. ;
Feagan, B. G. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (03) :292-302
[8]  
De Giulio B, 2005, WORLD J MICROB BIOT, V21, P739, DOI [10.1007/sl1274-004-4735-2, 10.1007/s11274-004-4735-2]
[9]   Encapsulation for preservation of functionality and targeted delivery of bioactive food components [J].
de Vos, Paul ;
Faas, Marijke M. ;
Spasojevic, Milica ;
Sikkema, Jan .
INTERNATIONAL DAIRY JOURNAL, 2010, 20 (04) :292-302
[10]   Secrets of the Bulgarian bacillus [J].
Dixon, B .
LANCET INFECTIOUS DISEASES, 2002, 2 (04) :260-260